Baidu
map

J Nucl Medicine:科学家开发的新“三步”系统在癌症小鼠身上实现了100%治愈率!

2017-11-03 枫丹白露 来宝网

纽约纪念斯隆凯特林癌症中心和波士顿麻省理工学院的研究人员开发了一个新的三步系统,使用核医学来瞄准和消除结直肠癌。在这项使用小鼠模型的研究中,研究人员达到了100%的治愈率 - 没有任何治疗相关的毒性作用。这项研究报告在“核医学杂志”11月份的专题文章中出现。

新系统治疗结肠癌能带来完全治愈】纽约纪念斯隆凯特林癌症中心和波士顿麻省理工学院的研究人员开发了一个新的三步系统,使用核医学来瞄准和消除结直肠癌。在这项使用小鼠模型的研究中,研究人员达到了100%的治愈率 - 没有任何治疗相关的毒性作用。这项研究报告在“核医学杂志”11月份的专题文章中出现。

到目前为止,使用抗体靶向放射性核素的实体瘤的放射免疫治疗(靶向治疗)成功有限。纪念斯隆凯特琳癌症中心的Steven M. Larson博士和Sarah Cheal博士解释说:“这项研究是非常新颖的,因为治疗方案所达到的基准,在治疗性肿瘤剂量方面,对身体正常组织无毒性的二次辐射。“小鼠肿瘤模型的成功来源于我们小组开发的试剂的独特质量,以及实践方法的减少,包括可以随时转化到临床患者身上的分析方法。”

Theranostics是一种来源于治疗和诊断的术语,是使用单一药物来诊断和治疗疾病。治疗是首先发现癌细胞,然后破坏它们,使健康的细胞不受伤害 - 使副作用最小化并改善患者的生活质量。

在这项研究中,在95%以上的原发和转移性人结直肠癌中发现抗原糖蛋白A33(GPA33)用A33肿瘤抗原的双特异性抗体和用于小分子放射性半抗原的二抗177(177Lu)和S-2-(4-氨基苄基)1,4,7,10-四氮杂环十二烷四乙酸(177Lu-DOTA-Bn)。

DOTA预靶向放射免疫疗法(PRIT)策略在小鼠模型上进行测试。在随机选择的正在接受治疗的小鼠中,使用系列SPECT / CT成像来监测治疗响应并计算对肿瘤的辐射吸收剂量。所有经DOTA-PRIT处理的动物均耐受良好的治疗,并且所有9只评估的小鼠在显微镜检查时均没有剩余的癌症痕迹。对重要器官,包括骨髓和肾脏也没有可检测的辐射损伤。

在小鼠模型中100%治愈率是一个有希望的初步发现,表明抗GPA33-DOTA-PRIT将是人类GPA33阳性结直肠癌肿瘤的有效放射免疫治疗方案。

根据疾病控制与预防中心的数据,结肠直肠癌是影响男性和女性的第三大常见癌症。美国每年大约有14万个新病例被确诊,5万人死于这种疾病。

这种核医学治疗方案的应用也可以扩展到其他癌症。 Larson和Cheal等人说:“如果在临床上取得成功,我们的方法将扩大肿瘤患者有效治疗的范围,该系统被设计成”即插即用“系统,允许使用许多针对人类肿瘤抗原的精细抗体,原则上适用于人体所有固体和液体肿瘤。“他们补充说:“在肿瘤学方面,尤其是对于实体瘤,对于晚期疾病的治愈性治疗存在巨大的需求,包括结肠癌,乳腺癌胰腺癌,黑色素瘤,肺癌和食管癌等等。

原始出处:

Sarah M. Cheal, Edward K. Fung, Mitesh Patel, et al. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. J Nucl Med November 1, 2017 vol. 58 no. 11 1735-1742.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2018-10-14 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-12-07 cenghis
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2018-05-18 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773672, encodeId=e6ca1e73672bb, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Oct 14 22:59:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988746, encodeId=c5d91988e4623, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Dec 07 11:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858822, encodeId=8b87185882251, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri May 18 23:59:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577573, encodeId=95bb15e75734a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608203, encodeId=2919160820301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 05 05:59:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258589, encodeId=77152585893f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Nov 04 11:53:50 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-11-04 清风拂面

    谢谢分享.学习了

    0

相关资讯

Lancet Public Health:降低饮用水砷浓度上限标准后每年可预防千例癌症发生

近期Lancet Public Health在线发表了来自美国国家健康与营养调查的数据,自2006年美国环保署(EPA)将公用水砷浓度上限标准从50ug/L下调至10ug/L后,每年可预防千例肺癌、膀胱癌和皮肤癌的发生。

DNA机器人或成治疗癌症的全新武器,有望超越电子机器人

作为纳米前沿科技快速发展的产物,加州理工大学“钱实验室”的DNA机器人步子又小又缓慢。它走一步需要5分钟,步长6纳米,差不多是人类一步的600万分之一。它只有20纳米长,大约是一粒米的千分之一。它看起来像根线虫,身子细长,没有脸,蛇一般缠来缠去。它的活动场地是一块DNA合成物的平板,隐藏在试管里——因为太小了,需要被注射进去。板子上分布着两种颜色的分子小球。这条“线虫”游来游去,捡起小球送到指

Nat Commun:重磅!科学家发现27种能阻止癌症的基因,你身上是否都有

通过对2000多种癌症的分析,科学家发现了27种可以阻止疾病的新基因。

肠道菌群可将抗癌药变毒药

我们已经知道每个人的基因组成对药物的代谢有很重要的影响。例如患者体内某些代谢酶的水平可能直接影响到药物的疗效和副作用。通过检测患者的基因特征来预测他们对药物的反应正在成为临床治疗的一个重要步骤。而日前在《Biofilms and Microbiomes》杂志上发表的一项研究表明,对于有些疗法来说,或许我们还要加上测量患者肠道细菌的种群特征。纽约爱因斯坦医学院(Albert Einstein Col

PNAS:抗衰老也许是徒劳!数学模型证明人类衰老不可避免

衰老是自然规律,但人们一直在努力阻止这一进程。一个悲伤的消息是,也许所有的尝试都是徒劳的——美国的研究人员已经证明,从数学模型上来看,阻止像人类这样多细胞有机体的衰老是不可能的。

eLife:科学家开发出新的检测技术,通过血液捕获癌症!

来自布里格姆妇女医院和达纳法伯癌症研究所的调查人员利用人工智能的力量开发出一种能早日准确检测卵巢癌的新技术。该小组已经确定了一个循环微小RNA网络 - 小的非编码遗传物质片段,与卵巢癌的风险相关,可以从血液样本中检测到。他们的发现在线上发表在eLife。

Baidu
map
Baidu
map
Baidu
map